Compendium of Cancer Genome Aberrations

Giant cell glioblastoma

Primary Author(s)*

Jay Alden, DO

Cancer Category/Type

  • Diffuse astrocytic and olidodendroglial tumors

Cancer Sub-Classification / Subtype

Glioblastoma, IDH-wildtype (IDH-wt)

Definition / Description of Disease

  • Rare histologic variant of IDH-wt glioblastoma [1]
  • Large, multinucleate giant cells with occasional abundant reticuln network [1]

Synonyms / Terminology

Epidemiology / Prevalence

  • Constitute <1% of glioblastomas [2]
  • May be more common in pediatric population [3]
  • Mean age 51 years [3]

Clinical Features

  • No evidence of a precursor lesion [1]
  • Presenting symptoms similar to IDH-wt glioblastoma
  • Radiographically and grossly circumscribed borders, may be mistaken for other neoplastic or non-neoplastic lesions [4]

Sites of Involvement

  • Localization similar to IDH-wt glioblastoma [3][2]

Morphologic Features

  • Bizarre, multi-nucleate giant cells with atypical mitotic figures [5]
  • Cells may contain numerous nuclei [1]
  • Palisading and ischemic necrosis [1]
  • Pseudo-rosette like perivascular tumor cell concentration [1]
 
Hematoxylin and Eosin stained section of giant cell glioblastoma showing bizarre multinucleate cells

Immunophenotype

Finding Marker
Positive (by definition) IDH-1
Positive (variable level) GFAP [6]
Positive (Majority) P53 [7] [6]
Negative (nearly universal) Neuronal Antigens [8]

Chromosomal Rearrangements (Gene Fusions)

Put your text here and/or fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence
EXAMPLE t(9;22)(q34;q11.2) EXAMPLE 3'ABL1 / 5'BCR EXAMPLE der(22) EXAMPLE 5%
EXAMPLE t(8;21)(q22;q22) EXAMPLE 5'RUNX1 / 3'RUNXT1 EXAMPLE der(8) EXAMPLE 5%

Characteristic Chromosomal Aberrations / Patterns

Put your text here

Genomic Gain/Loss/LOH

  • Near haploidization may be a primary oncogenic event underlying a subset of GCG's [9]
    • Recurrent loss of chromosomes 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 13, 14, 15, 17, 18, 19, 22
    • Typically have gains or retain heterozygosity of chromosome 7
  • Similar genomic findings have been described in other oncocytic tumors [10] [11] [12] [13]
  • Oncogenenesis in such cases may be related to widespread loss of tumor suppressors in a catastrophic reduplication event early in tumorigenesis [10]

Gene Mutations (SNV/INDEL)

Put your text here and/or fill in the tables

Gene Mutation Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence (COSMIC/TCGA/Other)
TP53 Tumor Suppressor 75-90% [14]
PTEN Tumor Suppressor 33% [15]
ATRX Tumor Suppressor Expression loss 19% [15]
TERT Telomerase 25% [15]
EGFR Oncogene Amplification 6% [15]

Other Mutations

Type Gene/Region/Other
Concomitant Mutations EXAMPLE IDH1 R123H
Secondary Mutations EXAMPLE Trisomy 7
Mutually Exclusive EXAMPLE EGFR Amplification

Epigenomics (Methylation)

  • MGMT promoter methylation may help predict response to alkylating chemotherapy [16]

Genes and Main Pathways Involved

Put your text here

Diagnostic Testing Methods

  • Diagnosis typically made based on morphology with immunohistochemical staining
    • GCG are typically distinguished from pleomorphic xanthastrocytoma by their lack of neuronal immunoreactivity [8]
  • Genomic testing for 1p/19q codeletion may help distinguish from oligodendroma

Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)

  • GCG's have a poor prognosis, but may have better outcome than conventional IDH-wt GB [17] [18] [3] [19] [2]
  • Median survival 13.5 months vs 9.8 for conventional IDH-wt GB [2]
  • May be better circumscribed than conventional IDH-wt GB, making these lesions risky for radiographic misdiagnosis and delayed therapy [4]

Familial Forms

Put your text here

Other Information

Put your text here

Links

Put your links here

Notes

References

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016. Pg 46-47
  2. ↑ 2.0 2.1 2.2 2.3 Ortega, Alicia; et al. (2014). "Treatment and survival of patients harboring histological variants of glioblastoma". Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia. 21 (10): 1709–1713. doi:10.1016/j.jocn.2014.05.003. ISSN 1532-2653. PMID 24980627.
  3. ↑ 3.0 3.1 3.2 3.3 Kozak, Kevin R.; et al. (2009). "Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis". Neuro-Oncology. 11 (6): 833–841. doi:10.1215/15228517-2008-123. ISSN 1523-5866. PMC 2802403. PMID 19332771.
  4. ↑ 4.0 4.1 Turner, Ryan; et al. (2018). "Imaging findings in the progression of a giant cell glioblastoma". Radiology Case Reports. 13 (5): 1007–1011. doi:10.1016/j.radcr.2018.07.010. ISSN 1930-0433. PMC 6097408. PMID 30128062.
  5. ↑ Margetts, J. C.; et al. (1989). "Giant-celled glioblastoma of brain. A clinico-pathological and radiological study of ten cases (including immunohistochemistry and ultrastructure)". Cancer. 63 (3): 524–531. doi:10.1002/1097-0142(19890201)63:33.0.co;2-d. ISSN 0008-543X. PMID 2912529.
  6. ↑ 6.0 6.1 Katoh, M.; et al. (1995). "Immunohistochemical analysis of giant cell glioblastoma". Pathology International. 45 (4): 275–282. doi:10.1111/j.1440-1827.1995.tb03456.x. ISSN 1320-5463. PMID 7550996.
  7. ↑ Peraud, A.; et al. (1997). "p53 mutations versus EGF receptor expression in giant cell glioblastomas". Journal of Neuropathology and Experimental Neurology. 56 (11): 1236–1241. doi:10.1097/00005072-199711000-00008. ISSN 0022-3069. PMID 9370234.
  8. ↑ 8.0 8.1 Martinez-Diaz, Hilda; et al. (2003). "Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin". Archives of Pathology & Laboratory Medicine. 127 (9): 1187–1191. doi:10.1043/1543-2165(2003)1272.0.CO;2. ISSN 1543-2165. PMID 12946225.
  9. ↑ Bigner, S. H.; et al. (1985). "A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line". Cancer Genetics and Cytogenetics. 18 (2): 141–153. doi:10.1016/0165-4608(85)90064-0. ISSN 0165-4608. PMID 3840409.
  10. ↑ 10.0 10.1 Ganly, Ian; et al. (2018). "Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes". Cancer Cell. 34 (2): 256–270.e5. doi:10.1016/j.ccell.2018.07.002. ISSN 1878-3686. PMC 6247912. PMID 30107176.
  11. ↑ Corver, Willem E.; et al. (2012). "Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma". PloS One. 7 (6): e38287. doi:10.1371/journal.pone.0038287. ISSN 1932-6203. PMC 3365880. PMID 22675538.
  12. ↑ Corver, Willem E.; et al. (2014). "Near-haploidization significantly associates with oncocytic adrenocortical, thyroid, and parathyroid tumors but not with mitochondrial DNA mutations". Genes, Chromosomes & Cancer. 53 (10): 833–844. doi:10.1002/gcc.22194. ISSN 1098-2264. PMID 24909752.
  13. ↑ Gopal, Raj K.; et al. (2018). "Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma". Cancer Cell. 34 (2): 242–255.e5. doi:10.1016/j.ccell.2018.06.013. ISSN 1878-3686. PMC 6121811. PMID 30107175.
  14. ↑ Martinez, Ramon; et al. (2007). "Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations". Cancer Genetics and Cytogenetics. 175 (1): 26–34. doi:10.1016/j.cancergencyto.2007.01.006. ISSN 0165-4608. PMID 17498554.
  15. ↑ 15.0 15.1 15.2 15.3 Oh, Ji Eun; et al. (2016). "Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma". Brain Pathology (Zurich, Switzerland). 26 (4): 517–522. doi:10.1111/bpa.12328. ISSN 1750-3639. PMID 26443480.
  16. ↑ Hegi, Monika E.; et al. (2005). "MGMT gene silencing and benefit from temozolomide in glioblastoma". The New England Journal of Medicine. 352 (10): 997–1003. doi:10.1056/NEJMoa043331. ISSN 1533-4406. PMID 15758010.
  17. ↑ Burger, P. C.; et al. (1980). "Histologic factors of prognostic significance in the glioblastoma multiforme". Cancer. 46 (5): 1179–1186. doi:10.1002/1097-0142(19800901)46:53.0.co;2-0. ISSN 0008-543X. PMID 6260329.
  18. ↑ Huang, M. C.; et al. (1996). "A clinico-immunohistochemical study of giant cell glioblastoma". Noshuyo Byori = Brain Tumor Pathology. 13 (1): 11–16. ISSN 0914-8108. PMID 8916121.
  19. ↑ Oh, Taemin; et al. (2014). "Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients". Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia. 21 (12): 2129–2134. doi:10.1016/j.jocn.2014.04.011. ISSN 1532-2653. PMID 25037316.
Retrieved from "https://ccga.io/index.php?title=Giant_cell_glioblastoma&oldid=7173"